INDV
Indivior Pharmaceuticals IncNASDAQHealthcare$30.47-0.59%ClosedMarket Cap: $3.80B
As of 2026-04-06
Valuation
P/E (TTM)
18.10
PEG
0.03
P/B
-38.80
P/S
3.06
EV/EBITDA
13.13
DCF Value
$2.79
FCF Yield
-2.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
80.3%
Operating Margin
24.4%
Net Margin
16.9%
ROE
-98.9%
ROA
17.4%
ROIC
80.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $358.0M | 82.1% | $122.0M | $103.0M | $0.79 | — |
| FY 2025 | $1.24B | 80.2% | $262.0M | $210.0M | $1.64 | — |
| Q3 2025 | $314.0M | 73.2% | $43.0M | $42.0M | $0.33 | — |
| Q2 2025 | $302.0M | 82.8% | $72.0M | $18.0M | $0.14 | — |
| Q1 2025 | $266.0M | 83.5% | $66.0M | $47.0M | $0.38 | — |
| Q4 2024 | $299.0M | 92.3% | $96.0M | $59.0M | $0.45 | — |
| FY 2024 | $1.19B | 80.6% | $32.0M | $2.0M | $0.02 | — |
| Q3 2024 | $307.0M | 77.5% | $4.0M | $4.0M | $0.03 | — |
| Q2 2024 | $299.0M | 73.6% | $-118.0M | $-97.0M | $-0.72 | — |
| Q1 2024 | $284.0M | 86.6% | $75.0M | $61.0M | $0.45 | — |
| Q4 2023 | $293.0M | 82.6% | $61.0M | $54.0M | $0.38 | — |
| FY 2023 | $1.09B | 84.1% | $-156.0M | $-129.0M | $0.01 | — |